Abstracts from the Indian National Stroke Conference (INSC) Held in Bangalore

s from the Indian National Stroke Conference (INSC) Held in Bangalore Abstract Number: 1 Presenting author: Deepti Vibha Email: deeptivibha@gmail.com Institute: All India Institute of Medical Sciences, New Delhi, IndiaNumber: 1 Presenting author: Deepti Vibha Email: deeptivibha@gmail.com Institute: All India Institute of Medical Sciences, New Delhi, India Abstract Title: Eligibility for Endovascular Treatment in the 6to 24-h Time Window: Retrospective Analysis of a Comprehensive Stroke Center in IndiaTitle: Eligibility for Endovascular Treatment in the 6to 24-h Time Window: Retrospective Analysis of a Comprehensive Stroke Center in India Introduction: The DAWN (6-24 h) and the DEFUSE-3 trials (6-16 h) have quadrupled the time window for endovascular thrombectomy up to 24 h. Aim: To identify the prevalence of thrombectomy-eligible patients in the 6-24-h time window at a comprehensive stroke center. Materials and Methods: A retrospective review of acute ischemic stroke (AIS) admissions was performed between July 2017 and September 2019. Eligibility for thrombectomy was explored based on DAWN and/or DEFUSE-3 trial criteria. Clinical trial-specific selection criteria were applied based on the presence of large vessel occlusion, baseline modified Rankin Scale score, and the Alberta Stroke Program Early Computerized Tomography Score (ASPECTS). Results: Out of 260 patients with AIS admitted within the study period, 32.7% (n = 85) presented within the 6to 24-h time window, and 72.3% (n = 188) had a National Institutes of Health Stroke Scale (NIHSS) ≥6. Based on NIHSS and time window criteria, 16.9% (44) and 17.7% (46) patients were potentially eligible for DAWN and DEFUSE-3 trial criteria, respectively. Further, 3.1% (8/260) and 2.7% (7/260) patients met DAWN and DEFUSE-3 trial criteria, including presence of anterior circulation large vessel occlusion and ASPECTS ≥6. In the 6-24-h window (85), 9.4% (8/85) and 8.2% (7/85) of patients met DAWN and DEFUSE-3 criteria, respectively. Conclusions: Of all patients with AIS presenting to a single comprehensive stroke center in the 6-24-h window, 9.4% and 8.2% of patients qualified for DAWN and DEFUSE-3 clinical trial criteria, respectively. These data predict a large potential for late-window thrombectomy in India.